Skip to content

Biohaven BHVN Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$3.47B-351%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$843.01M+73,142%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$531K+10,520%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$162.52M+27,078%
uniQure logo
uniQureQURE
$550K-99.3%
Roivant Sciences logo
Roivant SciencesROIV
$328.19M+220%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's financing cash flow?
Biohaven (BHVN) reported financing cash flow of $179.02M in Q1 2026.
How has Biohaven's financing cash flow changed year-over-year?
Biohaven's financing cash flow increased by 48413.8% year-over-year, from $369K to $179.02M.
What is the long-term trend for Biohaven's financing cash flow?
Over 4 years (2021 to 2025), Biohaven's financing cash flow has grown at a 33.5% compound annual growth rate (CAGR), from $138.45M to $439.12M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.